Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy.

Sobol, Paul T; Boudreau, Jeanette E; Stephenson, Kyle; Wan, Yonghong; Lichty, Brian D; Mossman, Karen L

Sobol, Paul T; Boudreau, Jeanette E; Stephenson, Kyle; Wan, Yonghong; Lichty, Brian D; Mossman, Karen L.

Affiliation

Sobol PT; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.

Mol Ther ; 19(2): 335-44, 2011 Feb.

Article in En | MEDLINE | ID: mdl-21119618

Subject(s)

Adaptive Immunity/immunology; Breast Neoplasms/immunology; Breast Neoplasms/therapy; Oncolytic Virotherapy/methods; Animals; CD8-Positive T-Lymphocytes/immunology; Cell Line, Tumor; Female; Humans; Mice; Simplexvirus/genetics; Simplexvirus/physiology

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Oncolytic Virotherapy / Adaptive Immunity Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Mol Ther Journal subject: BIOLOGIA MOLECULAR / TERAPEUTICA Year: 2011 Type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google